StockData
Onconetix, Inc. logo

Onconetix, Inc. (ONCO) stock

ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$3.15+0.15 (+5.00%)

Close on Nov 18, 2026Market cap $12.44MP/E –Yield –

Onconetix net income

Net income is the profit left for shareholders after every expense, interest and tax.

Onconetix's net income for the twelve months ending Jun 30, 2026 was -$10.20M. For fiscal 2025 it was -$14.03M. The highest annual figure on record is -$3.42M in fiscal 2021.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$14.03M–
FY2024Dec 31, 2024-$58.69M–
FY2023Dec 31, 2023-$37.41M–
FY2022Dec 31, 2022-$13.42M–
FY2021Dec 31, 2021-$3.42M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.87M–
Q1 FY2026Mar 31, 2026-$4.21M–
Q4 FY2025Dec 31, 2025$5.67M–
Q3 FY2025Sep 30, 2025-$8.78M–
Q2 FY2025Jun 30, 2025-$2.37M–
Q1 FY2025Mar 31, 2025-$8.55M–
Q4 FY2024Dec 31, 2024-$29.44M–
Q3 FY2024Sep 30, 2024-$3.83M–
Q2 FY2024Jun 30, 2024-$14.31M–
Q1 FY2024Mar 31, 2024-$11.12M–
Q4 FY2023Dec 31, 2023-$22.35M–
Q3 FY2023Sep 30, 2023-$5.35M–
Q4 FY2022Dec 31, 2022-$3.22M–
Q3 FY2022Sep 30, 2022-$3.87M–
Q2 FY2022Jun 30, 2022-$4.26M–
Q1 FY2022Mar 31, 2022-$2.07M–
Q4 FY2021Dec 31, 2021-$1.20M–
Q3 FY2021Sep 30, 2021-$1.10M–
Q2 FY2021Jun 30, 2021-$792.27K–
Q1 FY2021Mar 31, 2021-$325.78K–

More Onconetix figures

See a number that looks wrong?